Oral GLP-1 Comparison 2026: Aleniglipron vs Wegovy Pill vs Foundayo
Oral GLP-1 pills compared: aleniglipron 12.1% at 36 weeks, Wegovy pill, Foundayo, Rybelsus, elecoglipron — efficacy, dosing, food rules, FDA status.
Last reviewed
Quick answer: As of August 2026 the only FDA-approved oral GLP-1s for weight management are the Wegovy pill (oral semaglutide 25 mg, approved Dec 22, 2025) and Foundayo (orforglipron, approved Apr 1, 2026). The most effective oral GLP-1 in trial data is aleniglipron (GSBR-1290) — 12.1% average weight loss at 36 weeks in the Phase 2b ACCESS trial, and 16.3% placebo-adjusted at 44 weeks in ACCESS II — but it is investigational and not yet approved. This page compares every oral GLP-1 in or near the clinic: efficacy, dosing, administration rules, and regulatory status.
The oral GLP-1 landscape in one table
| Drug (molecule) | Company | Regulatory status | Dosing | Key efficacy result | Food rules |
|---|---|---|---|---|---|
| Wegovy pill (oral semaglutide 25 mg) | Novo Nordisk | FDA-approved Dec 22, 2025 (first oral GLP-1 for weight management); EU July 15, 2026 | Once daily; 1.5 → 4 → 9 → 25 mg | OASIS 4 (64 wk): 16.6% mean weight loss when adhered to; ~14% average | Empty stomach, ≤4 oz water, 30-min wait |
| Foundayo (orforglipron) | Eli Lilly | FDA-approved Apr 1, 2026; UK MHRA Aug 10, 2026 (first in Europe) | Once daily; 0.8–17.2 mg | ATTAIN-1 (72 wk): 12.4% (27.3 lb) on-treatment | Anytime — no food or water restrictions |
| Rybelsus (oral semaglutide) | Novo Nordisk | FDA-approved 2019 (first oral GLP-1 ever) — type 2 diabetes only | Once daily; 7/14 mg | Type 2 diabetes indication (not weight loss) | Empty stomach, 30-min wait |
| Aleniglipron (GSBR-1290) | Structure Therapeutics | Investigational — Phase 3 ACCOMPLISH-1 recruiting (Q3 2026 start) | Once daily; 5 mg start → 45/90/120 mg (up to 240 mg studied) | ACCESS (36 wk): 12.1% LS mean @ 120 mg; OLE up to 16.2% @ wk 56; ACCESS II 16.3%/16.0% @ 44 wk | With or without food |
| Elecoglipron | AstraZeneca | Investigational — Phase IIb VISTA (Lancet, Jun 2026); Phase III planned | Once daily; 75 mg (VISTA) | VISTA (36 wk): 11.8% | Once-daily oral tablet |
Earlier-stage pipeline: Roche’s CT-996, Ascletis’ ASC30, Viking’s oral VK2735 — Phase I–II.
Top picks: how we’d rank them today
For patients who can get a prescription now, the choice is between the two approved pills:
- Wegovy pill — best efficacy among approved orals. Posted 16.6% mean weight loss when treatment was adhered to (OASIS 4, 64 weeks) and ~14% on average in US News’ analysis. The trade-off: the strictest administration rules in the class — empty stomach, ≤4 oz of water, and a 30-minute wait before eating or drinking.
- Foundayo — best flexibility among approved orals. 12.4% on-treatment weight loss in ATTAIN-1 (72 weeks) and it can be taken anytime, with or without food. The first new-molecular-entity approval under the FDA’s National Priority Voucher pilot (Apr 1, 2026).
If aleniglipron is approved, it reshuffles the ranking. Its ACCESS II result — 16.3% placebo-adjusted weight loss at 44 weeks on 180 mg — is the highest efficacy signal for any oral GLP-1 to date, and like Foundayo it has no food restrictions. But it is an investigational drug: it cannot be prescribed, and anything sold online as “aleniglipron” is unapproved and unregulated. Treat it as the one to watch, not the one to buy.
What is aleniglipron (GSBR-1290)?
Aleniglipron is Structure Therapeutics’ once-daily oral small-molecule GLP-1 receptor agonist — a non-peptide chemical, unlike semaglutide-based pills. Because it is a small molecule, it can be taken with or without food, needs no refrigeration, and is designed to be manufactured at scale at lower cost. For the full breakdown of the Phase 2b ACCESS trial — design, dose-response, safety, and the open-label extension — see our aleniglipron explainer.
The Phase 2b ACCESS trial (Nature Medicine, June 5, 2026) randomized 230 adults with obesity or overweight across 38 US sites (Oct 28, 2024 – Feb 7, 2025). At week 36, least-squares mean weight change was:
| Dose | Weight change (LS mean) | Placebo-adjusted |
|---|---|---|
| 45 mg | −9.0% | −8.2% |
| 90 mg | −10.7% | −9.8% |
| 120 mg | −12.1% | −11.3% |
| Placebo | −0.8% | — |
At 120 mg, 86% of patients lost at least 5% of body weight, 70% at least 10%, and 38% at least 15%. There was no drug-induced liver injury and no deaths; 10.4% of participants discontinued, mostly due to GI effects early in titration. A prespecified interim analysis of the open-label extension (week 56) showed continued loss — up to 16.2% — and ACCESS II (44 weeks, doses to 240 mg) hit 16.3% placebo-adjusted at 180 mg with no plateau. One caveat: 12.1% is a group least-squares mean, not an individual maximum.
Wegovy pill vs Foundayo: the two approved pills
The Wegovy pill (oral semaglutide 25 mg) was the first oral GLP-1 approved for weight management (FDA, Dec 22, 2025). It delivers the strongest approved-pill trial numbers (16.6% when adhered to in OASIS 4) but requires an empty stomach, ≤4 oz of water, and a 30-minute wait after dosing — it uses an absorption enhancer (SNAC) to survive stomach acid.
Foundayo (orforglipron, Eli Lilly) is the second approved oral GLP-1 for obesity (FDA, Apr 1, 2026; UK MHRA Aug 10, 2026 — first in Europe). It’s a small molecule like aleniglipron, so it can be taken anytime with no food or water restrictions. On-treatment weight loss in ATTAIN-1 was 12.4% (27.3 lb) at 72 weeks.
Both are once-daily, refrigeration-free pills. If you can tolerate fasting rules, the Wegovy pill’s trial numbers are higher; if you want dosing flexibility, Foundayo wins.
Regulatory status: what’s approved vs what’s coming
No oral GLP-1 was FDA-approved in August 2026 — the timeline is:
- Wegovy pill — FDA Dec 22, 2025 (first oral GLP-1 for weight management); EU July 15, 2026
- Foundayo (orforglipron) — FDA Apr 1, 2026; UK MHRA Aug 10, 2026
- Rybelsus — 2019, first oral GLP-1 ever, but type 2 diabetes only
- Aleniglipron — investigational; End-of-Phase-2 meeting done; Phase 3 ACCOMPLISH-1 (NCT07654361) recruiting since July 13, 2026, on track for a Q3 2026 start at a 2.5 mg starting dose
- Elecoglipron (AstraZeneca) — Phase IIb VISTA data published (Lancet, Jun 2026); Phase III program planned
Follow the FDA peptide timeline tracker for approval updates, and see our coverage of the FDA’s GLP-1 compounding policy and the compounded GLP-1 ban push.
FAQ
Can you take oral GLP-1 for weight loss?
Yes — two oral GLP-1s are FDA-approved for weight management: the Wegovy pill (Dec 22, 2025) and Foundayo/orforglipron (Apr 1, 2026). Aleniglipron is not yet approved; it is available only through clinical trials.
What is aleniglipron?
Aleniglipron (GSBR-1290) is Structure Therapeutics’ investigational once-daily oral small-molecule GLP-1 receptor agonist. In the Phase 2b ACCESS trial it produced up to 12.1% average weight loss at 36 weeks (120 mg), with no drug-induced liver injury and no deaths. Phase 3 (ACCOMPLISH-1) is recruiting.
What is the strongest oral GLP-1?
By reported data, aleniglipron’s ACCESS II result — 16.3% placebo-adjusted weight loss at 44 weeks on 180 mg — is the highest efficacy signal for any oral GLP-1 to date, though it is investigational. Among approved pills, the Wegovy pill’s 16.6% (adherent OASIS 4 analysis) is the top figure. Cross-trial comparisons should be read with caution.
Can you take a GLP-1 pill with food?
It depends on the drug. Aleniglipron and Foundayo can be taken with or without food. The Wegovy pill must be taken on an empty stomach with ≤4 oz of water and a 30-minute wait before eating or drinking.
What are the side effects of oral GLP-1 pills?
Gastrointestinal effects dominate: nausea, vomiting, diarrhea, constipation, and decreased appetite. In ACCESS, nausea reached 71.1% and vomiting 44.6% in some dose groups — mostly mild to moderate and decreasing over time; 10.4% of aleniglipron patients discontinued, mostly due to GI effects early in titration.
How does aleniglipron compare to Wegovy pill and Foundayo?
On trial data, aleniglipron’s efficacy is at or above the approved pills (12.1% at 36 weeks; 16.3% placebo-adjusted at 44 weeks) and, like Foundayo, it has no food restrictions. The deciding factor is timing: aleniglipron won’t reach patients until its Phase 3 program completes.
Bottom line
The oral GLP-1 market now has two approved pills (Wegovy pill, Foundayo) and a high-efficacy investigational contender (aleniglipron) that would reshuffle the ranking if approved. Today, choose the Wegovy pill for the strongest approved-pill trial data or Foundayo for flexibility. Watch aleniglipron’s Phase 3 readouts — for the broader context on GLP-1s beyond the scale, see our explainer on GLP-1s and visceral belly fat.
Stay ahead of the GLP-1 and peptide landscape — subscribe to the PeptidesBeat newsletter for weekly research and regulatory digests, and follow the FDA peptide timeline tracker as the aleniglipron Phase 3 program gets underway.
PeptidesBeat is an independent editorial publication covering peptide research, policy, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Aleniglipron is an investigational drug not approved by the FDA; it is not available for clinical use outside registered trials. Consult a licensed healthcare provider for any medical question.
Educational content, not medical advice. © 2026 PeptidesBeat.